36 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
of significant need for innovative therapies that can demonstrate meaningful benefits beyond hemoglobin increase Disease Overview Market Opportunity No novel
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
companies and have helped to maximize the positive impact of innovative products for patient communities. I am thrilled she is joining the Agios team
8-K
EX-99.1
rgvf6vcv0j5a8
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
8-K
EX-99.1
og5m904lu8m7xz11
12 Jul 22
Agios Appoints Brian Goff as Chief Executive Officer
4:14pm
8-K
EX-99.1
r7ul2
5 May 22
Agios Reports Business Highlights and First Quarter 2022 Financial Results
7:21am
8-K
EX-99.1
wenb3e q1
11 Jun 21
Other Events
7:24am
DEFA14A
6j8wb
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
k428s 53q0sf190z
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
a7kgkiaogaw6cac
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
DEFA14A
EX-99.1
jf6oyk0 0ltofxfur
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
us2u9r vqvbej
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
t3kkp8 o17n8xp
12 Jun 20
Entry into a Material Definitive Agreement
7:04am